CERE Key Statistics, Chart & Performance
The current stock price of CERE is 44.96 USD. In the past month the price increased by 9.05%. In the past year, price increased by 100.09%.
CERE Latest News, Press Relases and Analysis
CERE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About CERE
Company Profile
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 355 full-time employees. The company went IPO on 2020-06-05. The firm is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The company focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Company Info
CEREVEL THERAPEUTICS HOLDING
222 Jacobs Street, Suite 200
Cambridge MASSACHUSETTS 02116 US
CEO: N. Anthony Coles
Employees: 355
Phone: 18443042048
CEREVEL THERAPEUTICS HOLDING / CERE FAQ
Can you describe the business of CEREVEL THERAPEUTICS HOLDING?
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 355 full-time employees. The company went IPO on 2020-06-05. The firm is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The company focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
What is the stock price of CEREVEL THERAPEUTICS HOLDING today?
The current stock price of CERE is 44.96 USD. The price increased by 0.74% in the last trading session.
Does CERE stock pay dividends?
CERE does not pay a dividend.
What is the ChartMill technical and fundamental rating of CERE stock?
CERE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for CEREVEL THERAPEUTICS HOLDING?
CEREVEL THERAPEUTICS HOLDING (CERE) has a market capitalization of 8.19B USD. This makes CERE a Mid Cap stock.
CERE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CERE. When comparing the yearly performance of all stocks, CERE is one of the better performing stocks in the market, outperforming 96.77% of all stocks.
CERE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CERE. CERE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CERE Financial Highlights
Over the last trailing twelve months CERE reported a non-GAAP Earnings per Share(EPS) of -2.73. The EPS decreased by -7.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.85% | ||
| ROE | -81.58% | ||
| Debt/Equity | 0.6 |
CERE Forecast & Estimates
14 analysts have analysed CERE and the average price target is 44.27 USD. This implies a price decrease of -1.54% is expected in the next year compared to the current price of 44.96.